Celgene Corp. on Monday said it agreed to buy Juno Therapeutics Inc. for $87 a share in cash, or about $9 billion, in a move that will expand Celgeneâ€™s portfolio of blood-cancer drugs.
The Wall Street Journal reported last week the two companies were in deal talks.

The deal will add a lymphoma treatment, expected to gain regulatory approval... To Read the Full Story Subscribe Sign In